Clinical Trial Detail

NCT ID NCT04395508
Title An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Recruitment Available
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors Genentech, Inc.

Her2-receptor positive breast cancer


Pertuzumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST